References
  1. Adamson P.C. Improving the outcome for children with cancer: Development of targeted new agents. CA Cancer J Clin . 2015;65(3): 212-20.
  2. Trout AT, Norris RE, de Blank PMK, Backus LR, Towbin AJ, Nash JM. Clinical trials: A plea to cooperative groups, consortia, pharmaceutical companies, and lead investigators for reasonable imaging protocols. Pediatr Blood Cancer . 2023;e30362.
  3. Packer R.J., Gajjar A., Vezina G., et al: Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. J Clin Oncol.(2006); (24): 4202-4208
  4. Michalski JM, Janss AJ, Vezina LG, et al. Children’s Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy with Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. J Clin Oncol . (2021); 39(24), 2685-269
  5. Jaju A, Li Y, Dahmoush H, et al. Imaging of pediatric brain tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee/ASPNR White Paper. Pediatr Blood Cancer . 2023;70(Suppl. 4):e30147.
  6. Leary SES, Packer RJ, Li Y, et al: Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children’s Oncology Group. JAMA Oncol.2021;7(9):1313-1321.
  7. Gottardo N.G., Leary S., Kang G., Gossett J., et al. (2020). How to increase survival in 7 to 10% of patients with average-risk medulloblastoma without new therapies: early prospective neuroradiology screening experience from the Children’s Oncology Group.Neuro-Oncology. (Supplement_3):Neuro Oncol. 22(Suppl 3): iii396